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Objective/Background.—To review the existing literature and describe a standardized methodology by expert consensus
for the performance of trigger point injections (TPIs) in the treatment of headache disorders. Despite their widespread use, the
efficacy, safety, and methodology of TPIs have not been reviewed specifically for headache disorders by expert consensus.
Methods.—The Peripheral Nerve Blocks and Other Interventional Procedures Special Interest Section of the American
Headache Society over a series of meetings reached a consensus for nomenclature, indications, contraindications, precautions,
procedural details, outcomes, and adverse effects for the use of TPIs for headache disorders. A subcommittee of the Section also
reviewed the literature.
Results.—Indications for TPIs may include many types of episodic and chronic primary and secondary headache disorders,
with the presence of active trigger points (TPs) on physical examination. Contraindications may include infection, a local open
skull defect, or an anesthetic allergy, and precautions are necessary in the setting of anticoagulant use, pregnancy, and obesity
with unclear anatomical landmarks. The most common muscles selected for TPIs include the trapezius, sternocleidomastoid,
and temporalis, with bupivacaine and lidocaine the agents used most frequently. Adverse effects are typically mild with careful
patient and procedural selection, though pneumothorax and other serious adverse events have been infrequently reported.
Conclusions.—When performed in the appropriate setting and with the proper expertise, TPIs seem to have a role in the
adjunctive treatment of the most common headache disorders. We hope our effort to characterize the methodology of TPIs by
expert opinion in the context of published data motivates the performance of evidence-based and standardized treatment
protocols.
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Trigger point injections (TPIs) have been per-
formed to treat a variety of musculoskeletal and neu-
rological disorders featuring pain for years.1 Trigger
points (TPs) are the hallmark physical examination
sign of myofascial pain,2,3 which may be present in
both primary and secondary headache disorders.4 The
pathophysiological mechanisms underlying TPs are
poorly understood. It has been suggested that TPs are
formed as a result of abnormal endplate potentials
that in turn lead to excessive acetylcholine release in
the neuromuscular junction.2,5 This process may result
in the formation of a taut band.The sustained muscle
contraction may lead to local ischemia, hypoxia, and
the release of algogenic substances that sensitize
peripheral nociceptors (peripheral sensitization).
Shah et al found significantly elevated concentrations
of various pain mediators (eg, substance P, calcitonin
gene-related peptide [CGRP], bradykinin, serotonin)
and other neurochemicals in the trapezius muscle of
patients with active TPs, as compared with those who
had latent TPs or healthy controls.6When the process
of peripheral sensitization is sustained, it may lead to
long-term electrophysiologic changes in dorsal horn
neurons and supraspinal structures, resulting in
central sensitization. This will manifest clinically with
hyperalgesia and allodynia.
TPs in head and neck areas have been associated
with various headache disorders.7-10 In one study,
an association was found between active TPs in the
upper trapezius, sternocleidomastoid, and tempo-
ralis muscles, and chronic tension-type headache
(CTTH).8 The presence of active TPs was associated
with greater intensity and longer duration of head-
ache in that study. Calandre et al examined the preva-
lence of TPs in migraine, which were found in 94% as
compared with 29% of controls.9 The number of TPs
was related to both attack frequency and disease
duration. The majority of TPs were found in the tem-
poral and sub-occipital areas. In another study by the
same group, TPs were found in all 12 patients with
cluster headache (CH) who were examined.10
The treatment of TPs includes both non-invasive
(eg, manual therapy, transcutaneous electrical nerve
stimulation [TENS]), and invasive modalities, includ-
ing TPIs and dry needling. Of these therapies, TPIs
are employed frequently to treat headache disorders
to alleviate head and neck pain. In a 2010 survey of
American Headache Society (AHS) membership,
75.3% of responders reported performing TPIs in the
treatment of headache.11 However, there has been no
consistent methodology proposed in this commonly
utilized therapy, and practice patterns may feature
marked heterogeneity in terms of indications, medi-
cations used, and technique.
The Peripheral Nerve Blocks & Other Inter-
ventional Procedures for Headache & Facial Pain
Section of the AHS (AHS-IPS) contains a member-
ship that shares a goal of standardizing “the
approaches, techniques, and indications of peripheral
nerve blocks and other interventional procedures in
headache management.”12 Despite the widespread
use by practitioners of such procedures,11 the overall
level of evidence is not strong, and until more ran-
domized controlled trials are performed, the support
for their use relies on experiential evidence, few con-
trolled studies, and expert opinion.
In pursuit of this goal, members of the AHS-IPS
reached a consensus for the methodology in the per-
formance of peripheral nerve blocks (PNBs) in the
treatment of headache disorders.13 As there is even
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less evidence for the use of TPIs,1 members of the
AHS-IPS aimed to also reach a consensus on their
performance in the treatment of headache disorders.
METHODS
This consensus statement was preceded by a sys-
tematic literature review that summarized the evi-
dence for the performance ofTPIs in the treatment of
headache.1 A follow-up literature review was also
conducted to survey the literature in discussing
potential primary and secondary headache disorder
indications for TPIs. A parallel study demonstrated
the need for a standardized methodology by practi-
tioners treating headache.11
The consensus was reached after a series of dis-
cussions at AHS-IPS meetings, including a prelimi-
nary review at the 2012 AHS annual scientific
meeting in Los Angeles, CA, a detailed point-by-
point discussion at the 2013 International Headache
Congress in Boston, MA, and a workshop of the
consensus statement at the 2013 AHS Scottsdale
Headache Symposium for finalization. The discus-
sions explicitly addressed nomenclature, indications,
contraindications and precautions, procedural details,
outcomes, and adverse effects. Throughout the
process a majority rule was required and achieved for
consensus. The manuscript was drafted and revised
by a subcommittee of the AHS-IPS (manuscript
authors) between and after the 2013 meetings.
RESULTS
Nomenclature and Definitions.—A myofascial TP
as described by Travell and Simons2 is a “hyperirri-
table spot in skeletal muscle that is associated with a
hypersensitive palpable nodule in a taut band.” The
spot will normally be painful to compression and
produce a stereotypical referral pattern to distant
structures. Travell and Simons have divided TPs into
subtypes, including active, associated, attachment,
central, key, latent, primary, secondary, and satellite.
For this discussion, only active and latent myofascial
TPs will be described.
A myofascial TP is considered active when it pro-
duces a clinical pain complaint. It will consistently be
tender to palpation and often cause motor dysfunc-
tion.An active myofascialTP will often elicit a “twitch
response” when stimulated. In some cases, along
with the characteristic referral pattern, autonomic
responses may be observed when the site is stimu-
lated. Also, active TPs may elicit spontaneous pain.
A myofascial TP is considered latent when it pro-
duces pain only with palpation, and it typically lacks
the characteristic referral pattern seen in active TPs.
A latent myofascial TP will share many of the clinical
characteristics of an active TP, such as motor dysfunc-
tion, and will reside in a taut band, but should not
produce spontaneous pain.14
Indications: Headache Disorders.—TPIs are often
used to treat headache and myofascial pain disorders,
though with limited evidence for efficacy. In a study
surveying the use of PNBs and TPIs in headache
treatment among American Headache Society
members,11 75.3% (122 practitioners) of the respon-
dents used TPIs as part of their headache manage-
ment (Table 1). The most common headache
diagnoses in which TPI were performed were chronic
tension-type headache (CTTH) (81.5%) and chronic
migraine (CM) (67.7%).
Strong evidence to indicate superiority of one
injectable agent (eg, local anesthetic, corticosteroid,
alpha-adrenergic antagonist, neurotoxin, non-
steroidal anti-inflammatory agent) over another
when performing TPIs for primary or secondary
headache disorders is lacking. A variety of agents,
doses, and volumes of agents have been used for
various headache diagnoses, though the use of local
Table 1.—Headache Diagnoses Treated With Trigger Point
Injections by American Headache Society Members in a
2010 Survey (Adapted from Blumenfeld et al11)
Headache Diagnoses
Percent of
Respondents
Chronic tension-type headache 81.5
Chronic migraine 67.7
New daily persistent headache 47.6
Status migrainosus 46.8
Episodic tension-type headache 41.1
Chronic cluster headache 30.6
Migraine without aura 29.8
Hemicrania continua 29
Migraine with aura 25
Episodic cluster headache 23.4
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anesthetics for TPIs in the literature predominates
and is consistent with our clinical experience.As such,
local anesthetics are our recommended medication
class for TPI in the treatment of headache disorders.
Recent data with respect to headache diagnoses and
therapy with TPIs are herein reviewed (Table 2).
Episodic Tension-Type Headache (ETTH).—In
a double-blinded, placebo-controlled randomized
study, lidocaine injections in the TPs of pericranial
muscles reduced the frequency and severity of pain at
2, 4, and 6 months compared with placebo (saline)
injections in patients with frequent ETTH.There was
greater improvement in patients receiving repetitive
lidocaine injections than in the single lidocaine injec-
tion or placebo groups.15
Chronic Tension-Type Headache (CTTH).—
OnabotulinumtoxinA has been used in patients with
CTTH with cervical myofascial TPs. In a randomized,
double-blind, placebo-controlled pilot study, patients
with CTTH who had onabotulinumtoxinA injected
into myofascial TPs initially showed a decreased
headache frequency; however, there was no differ-
ence in frequency at week 12 or in headache intensity
at any time point.16 Despite the lack of response at
this time frame, it may be plausible that the effects of
the toxin may subside before 12 weeks, and therefore
serial injections may be required for a more definitive
response, or a shorter ascertainment period is needed
to capture the appropriate duration of response.
In another randomized, double-blind, placebo-
controlled study, the effect of TPIs using lidocaine on
headache and other symptoms was examined in 48
patients with CTTH, though supraorbital, infraor-
bital, mental nerve and superior cervical ganglion
injections were also administered. After 3 treatment
sessions each 3 days apart, the number of headache
days per month, headache severity, analgesic use,
depression and anxiety all decreased, with lidocaine
showing a more robust effect than saline injections
after 3 months.17
Episodic and Chronic Cluster Headache.—One
case series identified at least one TP in 12 patients
with episodic and chronic cluster headache (CH).
Patients were injected in an uncontrolled fashion with
mepivacaine at 3 different circumstances: (1) during
an attack; (2) in an attempt to prevent an imminent
attack; (3) as a prophylactic therapy, with success
rates of 85%, 86%, and 88%. Seven of the 8 patients
with chronic CH had significant improvement with
TPIs when combined with prophylactic drug
therapy.10
Episodic and Chronic Migraine.—Fernandez-
de-las-Peñas et al identified TPs in neck and head
muscles in subjects presenting with unilateral
migraine and healthy controls, and a greater number
of patients with migraine had active TPs, though rates
of latent TPs were the same.18 Ashkenazi andYoung19
examined the effect of greater occipital nerve block
(GONB) withTPI (in most patients) on the reduction
of head pain and brush allodynia in patients with
episodic and transformed migraine. Acute headache
reduction was achieved in 89.5%, and the allodynia
scores were reduced in both trigeminal and cervical
dermatomes in all patients.
Garcia-Leiva et al20 evaluated TPIs in 52 patients
with migraine, of whom 61.5% had CM and 53%
had medication overuse, with prospective headache
diaries at baseline and during the 12-week treatment
period. Weekly injections of ropivacaine 10 mg
(1 mL) were performed for 12 weeks. In 9 (17.3%)
patients the frequency of attacks was reduced ≥50%.
There was 11%–49% reduction in the frequency of
attacks in 19 (36.5%) patients. A total of 31 (59.6%)
patients reported to be much or very much improved
after finishing the injection period. Rescue medica-
tion intake was reduced ≥50% in comparison with
baseline period in 11 (21.2%) and the attacks of
severe intensity decreased significantly. Eight
(26.6%) out of 30 patients suffering from CM
reverted to episodic migraine, though specific data
regarding the patients with CM and medication
overuse were not provided.
Cervicogenic Headache and Vestibular
Migraine.—Vestibular migraine (VM) has been
included in the appendix of the International Classi-
fication of Headache Disorders, 3rd edition beta.21
Baron et al reported improvement in patients with
suspected “cervically mediated” headache and dizzi-
ness that received both GONB and TPIs in a retro-
spective review.22 Improvements were seen in 57% of
patients with headache and 46% percent of patients
with dizziness. Other symptomatic improvement
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included neck range of motion (71%), neck pain
(52%), ear discomfort (47%), and tinnitus (30%).The
authors concluded that cervically mediated symptoms
may exist by influence of trigeminocervical and
vestibular circuitry through cervical afferent
neuromodulation.
Post-Traumatic Headache.—Packard reviewed
the data that suggest a plausible relationship of neck
injury and post-traumatic headache.23 The develop-
ment of TPs was included as a mechanism that may
contribute or lead to the development of post-
traumatic headache, and suggested thatTPIs may be a
treatment for this headache disorder, though no
studies have specifically addressed this question.
Indications: Physical Exam, Posture.—The key to
injection treatment of most primary headache disor-
ders is the identification of areas on the head and
neck that reproduce the patient’s headache pain.24,25
Most patients having migraine without aura, some
having migraine with aura, and most who have
tension-type headache (TTH) have myofascial TP
tenderness of muscles, ligaments, and tendons of the
head and neck which, when pressed, reproduce their
typical headache pain both during and between head-
ache episodes.2,26-28 Local anesthetic injection to these
tender areas can stop pain arising from them for
hours to months.13
The examiner can reliably identify taut bands in
muscles and the tender myofascial TPs within them
that reproduce the pain by pressing the symptomatic
areas with enough pressure to blanche the fingernail
or to elicit a report of discomfort.29 The pressure
needed to reproduce an element of the patient’s
typical headache may vary from patient to patient
and from site to site.2,3,30 Clinicians should exclude
structural causes of headache by examining eye
grounds, cranial nerves, and other parts of the nervous
system covered in the standardized neurologic exam.
The examiner should press or squeeze the trapezius
at the shoulder, sternocleidomastoid, splenius and
semispinalis capitis and cervicis, temporalis muscles
and the trochlear, masseter, and temporomandibular
areas to try to reproduce all aspects of the patient’s
headache pain.25,31-34 This technique may also elicit
non-headache symptoms of migraine, such as nausea,
photophobia, and phonophobia.2
Forward head posture, as measured by a variety
of techniques, occurs in many patients who have TTH
and also migraine without aura; it may be associated
with continuous myofascial strain of the neck exten-
sors, which could be a chronic source of local and
referred pain.18,35 Correction of forward head posture
may be an important but relatively unexplored aspect
in the treatment of primary and secondary headache
disorders.36
Contraindications and Precautions.—Contrain-
dications to TPI (Table 3) would include a local or
systemic infection, an open skull defect beneath the
injection site, or an allergy to anesthetic agents. For
patients on anticoagulation, we would recommend
checking an international normalized ratio (if taking
warfarin) before the procedure, spending extra time
palpating for and avoiding neighboring arteries, and
compressing over the injection site for 5–10 minutes.
If the patient is pregnant, lidocaine (FDA Category
B) would be preferred over bupivacaine (FDA Cat-
egory C) as an anesthetic, akin to PNBs.13 Pneumo-
thorax has been reported rarely after TPIs in the
cervicothoracic region, especially the trapezius.37,38 In
patients with unclear anatomical landmarks because
of body habitus, it may be reasonable to have trape-
zius injections performed with electromyographic39 or
ultrasound40 guidance.
Muscle Selection.—For the treatment of headache
disorders, the most commonmuscles selected forTPIs
include the trapezius (Fig. 1), sternocleidomastoid
(Fig. 2), and temporalis (Fig. 3) muscles.2,8 Other
muscles that may also feature TP-induced referred
pain to the head and neck include the cervical
paraspinal muscles (Figs. 4–6), masseter (Fig. 7),
levator scapulae (Fig. 8), frontalis, and occipitalis
(Fig. 3).2,41 The areas that the patient reports as
painful can be used as a marker for identifying the
muscles to be selected for TPI.
The trapezius (Fig. 1) is the most commonTP site
encountered in headache disorders.2 It can produce
pain in the temporal, jaw, occipital, and upper neck
areas.42This pain is usually ipsilateral to theTPand can
follow a hemicranial distribution. The sternocleido-
mastoid (Fig. 2) may be the second most common TP
site in headache disorders. It can refer pain to
the vertex, frontal, temporal, occipital, anterior neck,
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supraorbital areas, and temporomandibular joint,
depending on sternal vs clavicular involvement.42
Sternal division involvement may produce referred
pain to the unilateral, contralateral,or bilateral frontal
regions. If upper neck and occipital pain predominate,
the cervical paraspinal muscles (Figs. 4–6) should be
examined for aTP and can be considered for injection
as well.43 Although a levator scapulae TP (Fig. 8) is
more likely to produce pain in the inter-scapular area
and around the trapezius, rather than cranially, a
failure to inject the muscle can cause the trapezii to
remain active and cause difficulty with contralateral
sternocleidomastoid relaxation.2 The temporalis
(Fig. 3) often produces pain to the teeth, as well as
more distant temporal and supraorbital areas. If tem-
poromandibular joint dysfunction and tooth pain are
the predominant features of the patient’s pain,one can
consider injecting the masseter muscle (Fig. 7) along
with the temporalis.Although less common, the fron-
talis and occipitalis muscles (Fig. 3) can be injected if
pain is found at these corresponding areas.
Muscle Injections.—Before starting a TPI, the
patient should be seated in a chair or in a recumbent
position to prevent a vasovagal reaction.The injection
site should be cleaned with an alcohol solution.
A 22-, 25-, or 27-gauge, 1.5-inch needle can be used
Table 3.—Potential Precautions and Contraindications in the Performance of Trigger Point Injections for Headache
Patient Population Concern Action
Local anesthesia allergy Allergic reaction,
including anaphylaxis
Local anesthetic contraindicated
Use saline, corticosteroids, or other agents only
Vulnerability to neurally-mediated
syncope or hypotension
• First TPI series
• Pregnancy
• Elderly
• History of vasovagal events
• Dehydration
• Protracted headache attack
with nausea and/or vomiting
Near syncope
Syncope
Reduce concentration of anesthetic64
Limit number of total TPIs in a single session
Perform TPIs in supine or prone position, where feasible
Allow for extra time in the supine position after the procedure
as a precaution
Pregnancy Teratogenicity Local anesthetics may be preferable
Use lidocaine (FDA Category B) over bupivacaine (FDA
Category C)
Open skull defect
Craniotomy
Intracranial diffusion of
anesthetic agent
TPI may be contraindicated, but if benefits > risks inject at a
distance or contralateral from defect
Local or systemic infection
Immunocompromise
Abscess, cellulitis, myositis Avoid TPI
Anticoagulation therapy
Antiplatelet therapy
Hematoma Recent INR should be available if taking warfarin, and avoid
TPI if >3.0
Extra attention to palpate for (and avoid) neighboring arteries
Minimize total number of injection sites
Only perform TPI in superficial and easily compressible sites
Compress at each TPI site for 5-10 minutes
Cosmetic concerns Cutaneous or muscle
atrophy
Alopecia
Avoid corticosteroids
Obesity or thin body habitus
Unclear anatomical landmarks
Pneumothorax Avoid TPI in those regions, especially trapezius
Use a smaller needle (27 gauge)
Use EMG or sonographic guidance
EMG = electromyography; FDA = Food and Drug Administration; INR = international normalized ratio; TPI = trigger point
injections.
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for most superficial injections.A 21- or 22-gauge, 2- or
2.5-inch needle may be more favorable for deeper
muscles. Once the palpable band is correctly identi-
fied, the overlying skin is held and stabilized between
the thumb and index finger.This stabilizes the TP and
prevents it from rolling from the needle.The needle is
inserted 1 to 1.5 cm away from theTP and then slowly
advanced at a 30-degree angle into the TP. Once the
TP site is entered, the needle should be gently aspi-
rated to ensure that a blood vessel has not been punc-
tured. Subsequently, 0.1–0.3 cc of 1% lidocaine or
0.5% of bupivacaine should be injected.15 The needle
can be withdrawn slightly and then redirected to sur-
round the target, enabling reinjection multiple times
for a total volume of 2 to 4 mL. Hemostasis is
obtained by compression of the site for 2 to 4 minutes.
These injections may typically be performed
monthly,2,44 though there is some evidence for safety
and efficacy at more frequent intervals for at least
short spans of time in some studies.10,15,20 “Dry nee-
dling” or injection without the use of anesthetic medi-
cation has also been proposed to be useful in treating
TPs, as the needle itself may cause mechanical disrup-
tion of abnormally formed tissues that cause pain.2,45
Specific Muscle Injection Considerations (Adapted
From Simons et al2).—Trapezius.—The most
Fig 1.—Trigger point injections in the trapezius. The needle indicates a common trigger point and injection site. Arrows indicate
pain referral trajectories, with destinations outlined by dashed lines.
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common TPI site is the supra-clavicular region
(Fig. 1). For the injection, the patient may be posi-
tioned prone or leaning forward on a padded table
with the head resting on a pillow. The patient should
be positioned such that they are facing away from the
examiner. The upper trapezius can be injected poste-
riorly and superior to the scapula. For both sites, the
muscle is gripped between the thumb and the fingers
and pulled away to isolate it from the supraspinatus
muscle, the apex of the lung and also to prevent the
muscle from rolling under the needle. To accurately
identify the TP, the muscle is palpated for taut bands,
local twitches are activated, and the point of pain is
identified.The needle is inserted and directed upward
to avoid puncturing the lung.
Sternocleidomastoid.—For injection of the
sternal and clavicular divisions of the sternocleido-
mastoid muscle (Fig. 2), the patient may be seated or
lay supine.The head should be turned opposite to the
side being injected and tilted slightly down toward the
side of injection.A 22- or 25-gauge, 1.5-inch needle is
used for this injection. The bulk of the muscle is
grasped between the thumb and forefingers in order
to isolate it from underlying vessels. Before insertion
of the needle and anesthetic, the external jugular vein
must be located and avoided. To accurately identify
the TP, the muscle is palpated for taut bands, local
twitches are activated, and the point of pain is iden-
tified. The needle is then injected once and adjust-
ments may be made without withdrawing the needle.
Fig 2.—Trigger point injections in the sternocleidomastoid. Needles indicate common trigger points and injection sites. Arrows
indicate referred pain trajectories including trigger points in the sternal division (dashed arrows) and the clavicular division (solid
arrows), with destinations outlined by dashed (sternal division) or solid (clavicular division) lines.
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The sternal division is typically injected first because
of its easy accessibility medially. The clavicular divi-
sion is injected second, given that it is more posterior
and lateral. Only one side is typically injected at a
visit, to monitor the patient’s tolerability and pain
relief. Injecting the inferior part of the clavicular divi-
sion may be very challenging because it overlays the
apex of the lung and a pneumothorax could result.
The patient should be advised to rest in a recumbent
position for a few minutes after the procedure.
Cervical Paraspinal Muscles.—The cervical
paraspinal muscles consist of a layer of muscles with
the trapezius, splenius capitis, and splenius cervicis
being superficial and the semispinalis capitis, and
semispinalis cervicis being deeper.TPs in the splenius
capitis (Fig. 4) may refer pain to the vertex of the
head while TPs just inferior to this muscle in the
splenius cervicis (Fig. 5) can refer pain to the occipi-
tal, temporal, and retro-orbital areas as well as down
into the neck and shoulders. A safe injection site in
the splenius cervicis is just above the angle of the
neck, between the lower end of the splenius capitis
and the levator scapulae muscles, at the C7 vertebral
level. The needle is guided under the anterior border
of the trapezius to reach the TP while taking caution
to stay posterior to the transverse processes.
TPs in the semispinalis capitis (Fig. 6) and one
layer deeper in the semispinalis cervicis (Fig. 4) can
refer pain to the head, neck, and shoulders, usually
manifesting as suboccipital and upper back pain. A
safe site to inject the semispinalis capitis muscle is
located just above the base of the neck at the C4/C5
vertebral levels. The patient should be lying on the
side with head and neck support to keep the neck
straight; slight flexion of the neck may assist in TP
palpation, which is usually found 1–2 cm lateral to the
midline and 2–5 cm beneath the skin, trapezius, and
splenius capitis at the C4/C5 vertebral levels.Another
TP site can often be found just below the occipital
ridge at the insertion of the semispinalis capitis. This
site can refer pain around the head, focusing in the
temples and forehead. For this injection, the needle
should be angled upward toward the occipital bone to
avoid the vertebral artery.The semispinalis cervicis is
just under the semispinalis capitis and may also
contain TPs amenable to injection. The needle must
be advanced further (>5 cm) at the site described
above to reach this TP, but TPIs into this region must
be performed extremely cautiously and only by expe-
rienced practitioners because of the risk for potential
complications.
The vertebral artery is several centimeters
deeper than the cervical paraspinal muscles and is
protected by the transverse processes of the verte-
brae. If the needle is advanced too far for any cervical
paraspinal muscle TPI, especially from an extreme
lateral or medial approach, there is a risk of puncture.
To avoid this complication, it is helpful to visualize
and outline the suboccipital triangle and avoid
Fig 3.—Trigger point injections in the occipitalis, frontalis, and
temporalis. Needles indicate common trigger points and injec-
tion sites. Arrows indicate pain referral trajectories, with des-
tinations outlined by dashed lines.
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injection within this region. Furthermore, deep injec-
tions can lead to puncture of the epidural space in the
region of the foramen magnum, placing the patient at
risk for high epidural block.
Levator Scapulae.—The levator scapulae muscle
(Fig. 8) may be responsible for frequent tension in the
neck.TPIs of the muscle can help relieve this discom-
fort.The patient may be positioned sitting or lying on
their opposite side.The levator scapulae is inferior to
the trapezius and can be palpated underneath it.
Once the palpable band is correctly identified by the
methods described, the overlying skin is held and sta-
bilized between 2 fingers and the needle is directed
upward and medially toward the transverse process
of the vertebrae. This injection should be shallow to
avoid puncturing deeper structures (ie, thoracic cage).
If the patient continues to have soreness in the
levator scapulae referral pattern, have the patient
round the shoulders inward and palpate the superior
angle of the scapula, moving the fingers from side to
side to identify the TP. This injection should be
shallow, and directed upward to avoid causing a
pneumothorax.
Temporalis.—Injection of the temporalis muscle
(Fig. 3) can be complementary to injections in the
upper trapezius and sternocleidomastoid muscles
because they can all refer pain to the temples. The
patient is positioned lying supine with the head
turned to the opposite side.The temporal artery must
be palpated to avoid puncture, and then the muscle
Fig 4.—Trigger point injections in the semispinalis cervicis (left) and splenius capitis (right). Needles indicate common trigger
points and injection sites. Arrows indicate pain referral trajectories, with destinations outlined by dashed lines.
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can be identified by having the patient open and
clench the jaw closed.Once theTP is identified,main-
tain one finger over the temporal artery and inject
between 2 fingers, angling the needle upward. If TPs
remain, or there is restriction of jaw opening, injec-
tions may be repeated over 3 sites in the temporalis
muscle.
Masseter.—In order to inject themasseter (Fig. 7),
the patient should be positioned supine with the head
slightly tilted to the opposite side.The middle belly of
the masseter muscle may be identified by opening and
closing the jaw and palpating below the lower border
of the zygoma. The affected area is held between 2
fingers.The needle should be directed toward the pos-
terior portion of the ramus of the mandible.
Frontalis and Occipitalis.—The frontalis muscle
(Fig. 3) may be injected in addition to the sternoclei-
domastoid and temporalis muscles if pain is predomi-
nantly in the frontal area. A continuation of the
frontalis muscle posteriorly over the top of the head is
the occipitalis muscle (Fig. 3). It may be additionally
injected if pain is predominantly in the occipital area.
This muscle can be identified by having the patient
raise the eyebrows and palpating the back of the head.
Outcomes.—Several outcomes can be potentially
measured when performing TPIs for the treatment of
Fig 5.—Trigger point injections in the splenius cervicis. The needle indicates a common trigger point and injection site. Arrows
indicate referred pain trajectories, with destinations outlined by dashed lines.
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patients with acute exacerbations of a primary head-
ache disorders. Acutely, pain relief and pain freedom
can be measured at several time points up to 2 hours.
Sustained pain freedom can be measured at 24 hours
as recommended by the guidelines published by the
International Headache Society.46 The effect of pain
reduction is often immediate, within minutes of the
performance of TPIs.
If TPIs are being used for the prophylaxis of
headaches, the number of headache days, headache
attacks, disability scores, and days of medications
used after TPIs can be measured on a weekly or
monthly basis.On follow-up, one can also examine for
the transformation of an active TP into a latent TP.
Pain reduction at the local TP site and the referred
head pain site can also be measured. Pressure algom-
etry is an objective tool that can also be used to
measure the benefit of TPIs.47,48
In clinical practice, TPIs are often performed in
concert with other therapies, including the addition of
acute or prophylactic therapies, PNBs, cessation of
medication overuse, and non-pharmacological tech-
niques including stretching exercises and physical
therapy.Therefore, disentangling the influence ofTPIs
in isolation may be challenging and will require future
study.
Adverse Effects.—There are 5 primary potential
adverse effects (AEs) toTPIs, namely (1) direct nerve
Fig 6.—Trigger point injections in the semispinalis capitis. The needle indicates a common trigger point and injection site. Arrows
indicate referred pain trajectories, with destinations outlined by dashed lines.
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or muscle injury; (2) syncope; (3) anaphylaxis; (4)
hemorrhage; (5) infection.2,49,50 Direct damage to
nerve fibers can be minimized by using a small needle
(25 gauge or smaller) if feasible, performing straight
needle movements, and avoiding lateral movements.
Symptoms of nerve injury include new onset burning
pain, numbness, and paresthesia. Direct injury to the
muscle fiber can be avoided by staying away from
areas that appear inflamed or edematous. Careful
avoidance of vascular structures and minimization of
hematoma formation can also help reduce injury to
muscle fibers.
Intramuscular injection with local anesthetics can
cause reversible myonecrosis, especially in patients
receiving serial or high potency injections. Bupiva-
caine is the most likely local anesthetic to cause this
effect, while procaine is the least likely to be associ-
ated with this AE. Once treatment is discontinued,
muscle regeneration typically occurs in 3 to 4 weeks.50
Patients receiving TPIs are at risk for neurally-
mediated syncope, similar to other procedures fea-
turing injections. For this reason, patients should be
positioned in the recumbent position to decrease the
risk of falling, and also to minimize unexpected
movements. This is especially important in patients
who are not used to the procedure, or patients who
are volume depleted due to headache-associated
nausea and vomiting, are anxious, pregnant, or
elderly.
In order to minimize toxicity, doses should be
limited to less than 300 mg of lidocaine and 175 mg of
bupivacaine in a single injection series.51 Though
there is no clear weight-based consensus in the anes-
thesia literature for adults, maximum doses of
4.5 mg/kg lidocaine and 2 mg/kg bupivacaine have
been suggested.51,52 For the practitioner treating a
70 kg patient, such maximum volumes equate to
16 mL of 2% lidocaine and 28 mL of 0.5%
bupivacaine.
Anaphylaxis must be suspected if the patient
experiences hemodynamic instability shortly after a
low dose of local anesthetic. As noted previously,
patients should be screened for anticoagulant use and
worked up appropriately in order to avoid unantici-
pated hemorrhage. Excessive bleeding may also be
lessened by avoiding vascular structures and by
applying pressure to the injection site for several
minutes after the injection. As with most transcuta-
neous procedures, TPIs can be associated with skin
infections and cellulitis. The site of injection must
be cleaned with alcohol prior to the injection.
Immunocompromised patients are at higher risk for
infection; as such, both patients and clinicians should
proceed with caution.
Although the aforementioned 5 adverse risk
factors are the most commonly seen in clinical prac-
tice, it is important to note that there are serious AEs
reported in the current literature including pneumo-
thorax,37,38 intrathecal injection,53 and epidural
abscess formation.54
DISCUSSION
TPIs are commonly used by headache clinicians.
In a recentAHS survey, the most common indications
for performing TPIs were CTTH and chronic
Fig 7.—Trigger point injections in the masseter. The needle
indicates a common trigger point and injection site. Arrows
indicate referred pain trajectories, with a destination outlined
by a dashed line.
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migraine.11 TPIs were also reported to being used
fairly often for a variety of other headache disorders
in this survey. Despite the wide use of TPIs for head-
ache, data to support their use for this indication are
very limited.
TPIs have been mostly associated with
myofascial pain syndromes, and there are more data
on their use for these indications than for headache
disorders.55 The major objectives of TPIs are to
reduce pain and to restore function. In this setting,
TPIs have been performed using a variety of drugs
(local anesthetics, corticosteroids, non-steroidal anti-
inflammatory drugs, onabotulinumtoxinA), vitamins,
or fluids (eg, saline). Alternatively, inserting the
needle into or around the TP without injecting any
drug or fluid (“dry needling”) has been performed in
an attempt to relieve pain.55,56 However, data to
support the efficacy of this technique are scarce.57
Scott et al reviewed the efficacy of TPIs in various
musculoskeletal pain syndromes, finding that TPIs
relieved symptoms in patients with whiplash injury, as
well as in chronic head, neck, shoulder, and back
pain.55 However, the variability of study quality, tech-
niques used, and data reporting precluded any con-
clusions regarding the optimal method of injection or
drugs used. In general, TPIs were felt to be safe
Fig 8.—Trigger point injections in the levator scapulae. The needle indicates a common trigger point and injection site. Arrows
indicate referred pain trajectories, with destinations outlined by dashed lines.
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procedures by the authors although, as outlined pre-
viously, rare serious AEs have been reported. For
headache disorders, our consensus is to use local
anesthetics for TPIs and not other agents such as
corticosteroids based on our experience, available
literature reports to date, and the lack of a clear
biological rationale. For a related therapy, PNBs, the
addition of corticosteroids to local anesthetics does
not lead to added efficacy in migraine,19 though they
have efficacy in treating CH.58,59
There are several theories as to the mechanisms
by which TPIs may alleviate pain. It has been shown
in an animal study that needle insertion to the TP
region decreases muscle spontaneous electrical
activity if a local twitch response is elicited.60 This in
turn may disrupt the sequence of events that leads
to the formation of a taut band. Another theory is
that TPIs may prevent local ischemia and hypoxia in
the treated area. This may be attained through the
local trauma by the needle that results in the release
of vasodilators such as substance P and CGRP.61
Other investigators suggested that needle insertion
to a TP area activates Aβ and Aδ fibers, which in
turn suppress pain transmission centrally, based on
the gate control theory.62 In addition, some studies
suggest that needle insertion into a TP, combined
with electrical stimulation, may activate the endog-
enous opioid system resulting in enkephalin
release.63 Needle insertion into a TP area may exert
an analgesic effect through the phenomenon called
diffuse noxious inhibitory control (DNIC), also
known as conditioned pain modulation (CPM). In
this paradigm, a noxious stimulus applied remotely
may exert inhibitory effect on pain at the original
site of pain.56 It should be noted that the above
theories focus on the effect of the needle insertion
at the TP area, rather than that of any drug or fluid
injected, on pain.
More studies are needed to assess the effect of
TPIs on headache disorders, independent of the effect
of PNBs, which are often performed contemporane-
ously in clinical practice. In these future studies, the
patient population should be as homogenous as pos-
sible with regard to their headache diagnosis. In addi-
tion, the treatment protocols (indications for
treatment, location of injections, type, dose, and
volume of injected drugs) should be predetermined
and standardized. Outcome measures should be pre-
determined and be assessed in a blinded fashion.
Blinding may be challenging when local anesthetics
are used, as some patients will experience numbness
in the injection area after drug injection, whereas
those injected with placebo will not.
We hope our effort to characterize the method-
ology of TPIs by expert opinion in the context of
published data motivates the performance of such
trials. After obtaining and analyzing the results of
such studies, we may be able to design more rational,
evidence-based, and standardized treatment proto-
cols for the use of TPIs in various headache disorders.
In the interim, when performed in the appropriate
setting, patient selection, and with the proper ana-
tomic knowledge and technical expertise, TPIs seem
to have a role in the adjunctive treatment of the most
common headache disorders.
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